All In Biotech

NDA 021540 · Pharmacia

Caduet

Amlodipine Besylate, Atorvastatin Calcium · Oral

Last checked: Nov 20, 2026Latest source record: Nov 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Jan 30, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

656

178 Phase 3, 22 recruiting

FAERS reports

4,091

2,658 serious, 358 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 30, 2026.

CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. CADUET is a combination of amlodipine besylate, a calcium channel blocker, and atorvastatin calcium, a HMG-CoA-reductase inhibitor (statin), indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate ( 1 ). Amlodipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Amlodipine is indicated for the treatment of Coronary Artery Disease ( 1 ). Atorvastatin is indicated ( 1 ): • To reduce the risk of: o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. o MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. o Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD. • As an adjunct to diet to reduce low-density lipoprotein (LDL-C) in: o Adults with primary hyperlipidemia. o Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia. • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Amlodipine Hypertension Amlodipine is indicated for the treatment of hypertension,...

Mechanism: CADUET is a combination of two drugs, a dihydropyridine calcium channel blocker (amlodipine) and an HMG-CoA reductase inhibitor (atorvastatin). The amlodipine component of CADUET inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The atorvastatin component of CADUET is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Amlodipine Amlodipine binds to both dihydropyridine and nondihydropyridine binding...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

11 products under this application
  • CADUET · AMLODIPINE BESYLATE EQ 2.5MG BASE; ATORVASTATIN CALCIUM EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
  • CADUET · AMLODIPINE BESYLATE EQ 10MG BASE; ATORVASTATIN CALCIUM EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
  • CADUET · AMLODIPINE BESYLATE EQ 10MG BASE; ATORVASTATIN CALCIUM EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
  • CADUET · AMLODIPINE BESYLATE EQ 2.5MG BASE; ATORVASTATIN CALCIUM EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
  • CADUET · AMLODIPINE BESYLATE EQ 5MG BASE; ATORVASTATIN CALCIUM EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
  • CADUET · AMLODIPINE BESYLATE EQ 5MG BASE; ATORVASTATIN CALCIUM EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
  • CADUET · AMLODIPINE BESYLATE EQ 10MG BASE; ATORVASTATIN CALCIUM EQ 80MG BASE · TABLET, ORAL · Prescription · TE AB
  • CADUET · AMLODIPINE BESYLATE EQ 10MG BASE; ATORVASTATIN CALCIUM EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
  • CADUET · AMLODIPINE BESYLATE EQ 5MG BASE; ATORVASTATIN CALCIUM EQ 80MG BASE · TABLET, ORAL · Prescription · TE AB
  • CADUET · AMLODIPINE BESYLATE EQ 2.5MG BASE; ATORVASTATIN CALCIUM EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
  • CADUET · AMLODIPINE BESYLATE EQ 5MG BASE; ATORVASTATIN CALCIUM EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Amlodipine" as an intervention, any sponsor and status, largest first.

All 656 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness184
  • drug ineffective178
  • nausea178
  • fatigue175
  • malaise163
  • pain148
  • dyspnoea146
  • death144
  • headache133
  • hypertension133
  • asthenia126
  • diarrhoea124

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
200552
2006102
2007193
2008169
2009217
2010622
2011291
2012356
2013275
2014250
2015226
2016176
2017161
2018129
2019177
2020199
2021105
202298
202389
202479
202564
202657

Recalls

2 FDA enforcement reports for this application.

  • Feb 5, 2020 · Class II · Terminated

    Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.

  • Feb 5, 2020 · Class II · Terminated

    Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Caduet (Amlodipine/Atorvastatin)

2024 spending

$395K

Beneficiaries

68

248 claims

Per beneficiary

$5,804

$21.92 per unit

View as table
YearSpending
2020$3,144,281
2021$1,444,023
2022$926,526
2023$385,568
2024$394,684

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,807 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.